Louise Emmett will make an oral presentation to the SNMMI annual...

Louise Emmett will make an oral presentation to the SNMMI annual meeting tomorrow, based on an abstract presented to SNMMI many months ago.

See: ​

https://tinyurl.com/y2ths6ta[/BCOLOR]​

We know from the abstract that the response rate after two sessions of combination therapy was much better than anything achieved by LuPSMA monotherapy (which Novartis recently bought for $2.1 Billion); and that treatment was well tolerated.  Hopefully Louise will update these data in her address.

It's funny sometimes how things work out.  GK invented Idronoxil more than 20 years ago, was on death's door when he discovered a way to overcome delivery problems, and promptly cured his prostate cancer.  Some time later, Louise unexpectedly asked whether she could try NOX66 in combination with LuPSMA and GK agreed, figuring there was nothing to lose, and we now see that Louise's vision came true.  We already know that DARRT-type treatment is quick and seems to be effective; and lately we have learnt of the discovery that Veyonda happens to be a STING agonist, which explains why abscopal responses have occurred.

Looking good, Noxopharm!